Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Retrospective 1-Year Observational Study Assessing Efficacy Tolerability And Conversion To Monotherapy With Eslicabazepine Acetate In Patients With Partial-Onset Seizures Who Failed On A First Line Monotherapy.

X
Trial Profile

A Multicenter Retrospective 1-Year Observational Study Assessing Efficacy Tolerability And Conversion To Monotherapy With Eslicabazepine Acetate In Patients With Partial-Onset Seizures Who Failed On A First Line Monotherapy.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies; Seizures
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EARLY-ESLI study
  • Most Recent Events

    • 06 Dec 2016 Results assessing efficacy, tolerability and conversion to monotherapy with Eslicarbazepine Acetate after first montherapy failure, presented at the 70th Annual Meeting of the American Epilepsy Society.
    • 27 Sep 2016 New trial record
    • 12 Sep 2016 Results from this study were presented at the 12th European Congress on Epileptology (ECE) 2016, according to an Eisai Co Ltd media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top